Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer

Li, XJ; Huang, JS; Wang, FH; Jiang, Q; Huang, LL; Li, SP; Guo, GF

Guo, GF (通讯作者)，Sun Yat sen Univ, VIP Dept, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.;Guo, GF (通讯作者)，Sun Yat sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.;Li, SP; Guo, GF (通讯作者)，Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China.;Li, SP (通讯作者)，Sun Yat sen Univ, State Key Lab Oncol South China, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.;Li, SP (通讯作者)，Sun Yat sen Univ, Dept Pancreaticobiliary Surg, Canc Ctr, Guangzhou, Peoples R China.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023; 15 ():

Abstract

Background:Modified fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) regimen (mFOLFIRINOX), comprised of fluorouracil, leucovorin, irinotec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索